KRAS and neoplasm: Over all subsequent lines of therapy, 54 (24.7%) of the 219 patients with WT KRAS tumours had no subsequent therapy, 109 patients (49.8%) received anti-EGFR therapy, and 56 patients (25.6%) received no anti-EGFR therapy.